References
- HoskingDChilversCEChristiansenCPrevention of bone loss with alendronate in postmenopausal women under 60 years of ageN Engl J Med19983388 485 4929443925
- RussellRGRogersMJBisphosphonates: from the laboratory to the clinic and back againBone1999251 97 10610423031
- FinkelsteinJSWylandJJLeeHNeerRMEffects of teriparatide, alendronate, or both in women with postmenopausal osteoporosisJ Clin Endocrinol Metab2010954 1838 184520164296
- FleischHBisphosphonates in osteoporosisEur Spine J200312suppl 2 S142 S14613680318
- AnanchenkoGNovakovicJTikhomirovaAAlendronate sodiumProfiles Drug Subst Excip Relat Methodol201338 1 3323668401
- PorrasAGHollandSDGertzBJPharmacokinetics of alendronateClin Pharmacokinet1999365 315 32810384857
- CocquytVKlineWFGertzBJPharmacokinetics of intravenous alendronateJ Clin Pharmacol1999394 385 39310197297
- BlumeHHMidhaKKBio-International 92, conference on bioavailability, bioequivalence, and pharmacokinetic studiesJ Pharm Sci19938211 1186 11897904641
- ShahVPYacobiABarrWHEvaluation of orally administered highly variable drugs and drug formulationsPharm Res19961311 1590 15948956322
- DavitBMConnerDPFabian-FritschBHighly variable drugs: observations from bioequivalence data submitted to the FDA for new generic drug applicationsAAPS J2008101 148 15618446515
- TothfalusiLEndrenyiLArietaAGEvaluation of bioequivalence for highly variable drugs with scaled average bioequivalenceClin Pharmacokinet20094811 725 74319817502
- ZhangXZhengNLionbergerRAYuLXInnovative approaches for demonstration of bioequivalence: the US FDA perspectiveTher Deliv201346 725 74023738669
- DavitBMChenMLConnerDPImplementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug AdministrationAAPS J2012144 915 92422972221
- García-ArietaAGordonJBioequivalence requirements in the European Union: critical discussionAAPS J2012144 738 74822826032
- Committee for Medicinal Products for Human Use (CHMP)Guideline on the Investigation of BioequivalenceLondonEuropean Medicines Agency (EMA)2010
- Office of Generic Drugs, Food and Drug Administration (FDA)Draft Guidance for Industry on Bioequivalence Recommendations for Progesterone Capsules2011 Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM209294.pdfAccessed May 29, 2017
- HoweWGApproximate confidence limits on the mean of X + Y where X and Y are two tabled independent random variablesJ Am Stat Assoc197469347 789 794
- EMEA, CHMP Efficacy Working Party Therapeutic Subgroup on Pharmacokinetics (EWP-PK)EMA Questions & Answers: Positions on Specific Questions Addressed to the Pharmacokinetics Working Party, EMA/618604/2008 Rev. 31262011
- ThudiNRGagnonSHussainSTwo-way crossover bioequivalence study of alendronate sodium tablets in healthy, non-smoking male volunteers under fasted conditionsArzneimittelforschung20095910 521 52519998580
- RhimSYParkJHParkYSBioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteersClin Ther2009315 1037 104519539104
- WrightDHMolsRBrownKRBioequivalence of alendronate and vitamin d3 in a combination tablet versus corresponding-dose individual tablets in healthy Taiwanese volunteers, determined using a novel plasma alendronate assayCurr Ther Res Clin Exp201577 116 12126843897
- KaralisVSymillidesMMacherasPBioequivalence of highly variable drugs: a comparison of the newly proposed regulatory approaches by FDA and EMAPharm Res2012294 1066 107722203326